A study published online 16 October 2026 in the Journal of the American Academy of Dermatology takes on a question that has hovered over hidradenitis suppurativa care for years: what should clinicians actually do with the established association between HS and lymphoma?

The paper, authored by Wangxing Wang and Sai Fan, is titled "Making lymphoma risk in hidradenitis suppurativa clinically actionable." That framing matters. It signals a shift from epidemiology toward practice guidance — from risk documentation to risk management.

What does the title tell practitioners?

The literature on HS and lymphoma has largely lived in registries and claims databases. Associations exist. The clinical follow-through has not. Wang and Fan's contribution, per the published title, is an attempt to close that gap — to convert population-level risk into steps a dermatologist can take in the exam room.

For an HS cohort that already carries substantial morbidity, that's not academic housekeeping. HS patients sit under long-term immunomodulation in many cases, often on biologics such as TNF inhibitors, and chronic systemic inflammation is part of the disease itself. Any lymphoma signal therefore raises twin questions: is the risk driven by the disease, the drugs, or both — and who needs surveillance?

The paper does not appear, from the publication record available, to report a new effect size or hazard ratio as its headline. Its stated aim is actionability. That distinction shapes how practitioners should read it: less "how large is the risk," more "what do I do Monday morning."

Why HS and lymphoma?

Hidradenitis suppurativa is a chronic inflammatory follicular disorder affecting apocrine gland–bearing skin, with Hurst staging and Hurley staging commonly used to grade severity. Chronic antigenic stimulation and sustained immune activation are recognized mechanisms theorized to link inflammatory disease with lymphoid malignancy.

The editorial in JAAD — a journal whose readership spans general dermatology and complex medical dermatology — signals editorial confidence that this risk discussion has matured enough for a practice-facing treatment.

What does this change for the clinic?

For dermatologists managing moderate-to-severe HS, the practical question is whether the paper gives them a surveillance or counseling framework. Does it define a higher-risk subgroup? Does it propose symptom thresholds that should trigger referral? The title's promise of "clinically actionable" guidance suggests at least one of these.

Immunology-adjacent clinicians will also watch for drug-safety implications. If the authors separate disease-driven risk from therapy-driven risk, that informs consent conversations around biologic initiation, where lymphoma warnings already feature in labeling discussions.

Practitioners should also note the date. Online publication on 16 October 2026 means the print assignment and full indexing are likely to follow, and citation — including in guideline discussions — will build from here.

The takeaway

Derm Field will monitor the full text as it propagates through indexing services. For now, the signal to the field is clear: HS-associated lymphoma risk is moving from an epidemiological footnote toward a management conversation, and Wang and Fan's October 2026 paper in JAAD appears to be the vehicle for that move.